Large hospitals waiting for the launch of the new obesity drug ‘Belviq’
The new obesity drug, ‘Belviq,’ has been exceptionally noticeable among doctors.
Belviq has attracted doctors as a new obesity drug, which would be first launched since the last obesity drug in 13 years. Shinhan Investment Corp. confirmed the distribution quantity of Belviq at KRW 5.3 billion in...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
